BioCryst Pharmaceuticals (BCRX) said Monday that the Health Services Executive in Ireland has recommended Orladeyo for the routine prevention of recurrent attacks of hereditary angioedema in patients who are at least 12 years old.
The decision follows European Commission marketing authorization of the drug, also called berotralstat, in April 2021.
The orally ingested, once-daily drug is designed to prevent hereditary angioedema attacks by decreasing the activity of plasma kallikrein, the company said.
Price: 8.50, Change: +0.07, Percent Change: +0.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments